Your session is about to expire
← Back to Search
Ruxolitinib Continuation for Cancer
Study Summary
This trial is for subjects who have completed an Incyte-sponsored study of ruxolitinib and will continue receiving the drug, ruxolitinib plus cancer therapy, or just cancer therapy. The purpose is to monitor safety and adverse events.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 149 Patients • NCT02038036Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can get ruxolitinib or other cancer treatments not provided by the study.I am currently seeing positive effects from my cancer treatment, as confirmed by my doctor.My condition is not worsening according to my doctor.
- Group 1: Ruxolitinib
- Group 2: Ruxolitinib plus background cancer therapy
- Group 3: Background cancer therapy alone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people can join this experiment at most?
"This study is not recruiting at this time. The trial was originally posted on 11/30/2016 and was last updated on 7/6/2022. There are presently 2685 trials actively searching for participants with breast cancer and 508 studies for Ruxolitinib actively looking for participants."
How is Ruxolitinib used to help patients?
"Ruxolitinib is often used to treat polycythemia vera. However, it can also be an effective medication for patients that are resistant or intolerant of hydroxyurea, have metastatic colorectal carcinoma, and/or primary myelofibrosis."
Does Ruxolitinib have a good safety profile?
"While there is some data supporting the safety of Ruxolitinib, it did not receive a higher score because Phase 2 trials have yet to confirm efficacy."
Ruxolitinib has been investigated before, correct?
"Ruxolitinib was first researched in 2002 at National Institutes of Health Clinical Center. As of now, 725 clinical trials have been completed with 508 live studies. A large portion of these ongoing trials are taking place in Louisville, Kentucky."
Are patients still being recruited for this experiment?
"The clinicaltrials.gov database reveals that this trial is not currently recruiting patients. The listing was created on 30/11/2016 and updated on 06/07/2022. Although this study is no longer looking for participants, there are 3193 other trials with open recruitment at present."
Share this study with friends
Copy Link
Messenger